Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.
Stay up to date on practice-changing data in community practice.
CheckMate 274 Confirms Benefit of Nivolumab for Bladder Cancer
During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in patients with high PD-L1.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
FDA to Review Nogapendekin Alfa in Bladder Cancer and Lymphopenia
A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus Calmette-Guérin in papillary non-muscle invasive bladder cancer.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
FDA Greenlights Bevacizumab Biosimilar Across Cancer Types
The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.
Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer
Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.